Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 18/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 15/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712339 | 0.96 | ADRA1A (0.55) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7971514 | 0.94 | MCHR1 (0.54) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6710986 | 0.92 | ADRA1A (0.72) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7524292 | 0.91 | ADRA1A (0.52) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6848609 | 0.90 | ADRA1A (0.51) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6710985 | 0.90 | ADRA1A (0.71) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL6848930 | 0.90 | ADRA1A (0.70) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6713890 | 0.90 | ADRA1A (0.53) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7528253 | 0.87 | ADRA1A (0.71) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7526070 | 0.87 | ADRA1A (0.61) | ADRA1AMCHR1DRD2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | ADRA1A 4/4885MCHR1 909/4885DRD2 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.